首页> 外国专利> An anti-cancer adjuvant composition comprising a receptor-coupled protein kinase-3 (RIP3) expression promoter as an active ingredient, and an anti-cancer adjuvant that promotes the sensitivity of the anti-cancer drug by promoting the expression of receptor-coupled protein kinase-3 (RIP3) Screening method and anticancer drug sensitivity monitoring method

An anti-cancer adjuvant composition comprising a receptor-coupled protein kinase-3 (RIP3) expression promoter as an active ingredient, and an anti-cancer adjuvant that promotes the sensitivity of the anti-cancer drug by promoting the expression of receptor-coupled protein kinase-3 (RIP3) Screening method and anticancer drug sensitivity monitoring method

机译：一种抗癌佐剂组合物，其包含受体偶联蛋白激酶-3（RIP3）表达启动子作为活性成分，以及通过促进受体偶联蛋白的表达来促进抗癌药的敏感性的抗癌佐剂。激酶3（RIP3）的筛选方法和抗癌药敏性监测方法

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to a pharmaceutical composition for assisting anti-cancer, comprising a receptor-coupled protein kinase-3 (RIP3) protein expression promoter or activator as an active ingredient. In addition, the present invention provides a method for enhancing cancer cell death, comprising administering a receptor-coupled protein kinase-3 (RIP3) protein expression promoter or activator and an anticancer agent to a cancer cell in combination. Furthermore, the present invention uses a screening method for an anti-cancer auxiliary agent that promotes the expression of receptor-coupled protein kinase-3 (RIP3) and enhances the sensitivity of the anti-cancer drug, and whether or not receptor-coupled protein kinase-3 (RIP3) is expressed. The present invention relates to a method for monitoring anticancer drug sensitivity. Thus, for patients lacking receptor-coupled protein kinase-3 (RIP3) expression, after pretreatment with a demethylating agent to induce receptor-coupled protein kinase-3 (RIP3) expression, conventional The use of chemotherapeutic agents is expected to be an effective treatment strategy. In addition, it is expected to be an effective strategy for monitoring anticancer drug sensitivity in anticancer treatment and screening for anticancer adjuvants that enhance anticancer drug sensitivity.

机译：本发明涉及用于辅助抗癌的药物组合物，其包含受体偶联的蛋白激酶-3（RIP3）蛋白表达启动子或活化剂作为活性成分。另外，本发明提供了用于增强癌细胞死亡的方法，其包括对癌细胞联合施用受体偶联的蛋白激酶-3（RIP3）蛋白表达启动子或活化剂和抗癌剂。此外，本发明使用抗癌辅助剂的筛选方法，所述抗癌辅助剂促进受体偶联蛋白激酶-3（RIP3）的表达并增强抗癌药的敏感性，以及是否受体偶联蛋白。表达激酶3（RIP3）。本发明涉及一种监测抗癌药物敏感性的方法。因此，对于缺乏受体偶联蛋白激酶3（RIP3）表达的患者，在用去甲基化剂预处理以诱导受体偶联蛋白激酶3（RIP3）表达后，常规的化学治疗药物有望成为一种有效的治疗方法。战略。另外，预期它将是在抗癌治疗中监测抗癌药物敏感性和筛选增强抗癌药物敏感性的抗癌佐剂的有效策略。

著录项

公开/公告号JP2017511812A

专利类型
公开/公告日2017-04-27

原文格式PDF
申请/专利权人ドン・ワ・ファーム・カンパニー・リミテッド;
展开▼

申请/专利号JP20160568771
发明设计人キム;ヨウ・スン;コオ;ギ・バン;ユン;ジュン・ホ;キム;ウォ・ジュン;ジョ;ユ・ナ;
展开▼

申请日2014-11-25
分类号A61K45;C12Q1/68;C12Q1/04;A61K31/7008;A61K31/7048;A61P35;A61K38;A61K39/395;A61P43;A61K45/06;A61P15;A61P1/16;A61P1;G01N33/53;G01N33/573;G01N33/50;G01N33/15;
国家 JP
入库时间 2022-08-21 13:58:31

相似文献

专利
外文文献
中文文献